Rigel Announces Presentations At The Upcoming 2024 ASCO Annual Meeting And EHA2024 Hybrid Congress
(MENAFN- PR Newswire) Oral presentation of final five-year results from the registrational Phase 2 trial in R/R mIDH1 AML patients reinforces REZLIDHIA® (olutasidenib) efficacy in heavily pretreated patients, including those receiving prior venetoclax …